13F Holdings
中文EN

APUS Apimeds Pharmaceuticals US, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1894525 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-341.0%
TTM EPS YoY-84.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-30.6%
ROA-27.9%
ROIC (approx.)-26.2%
Asset turnover—

Leverage & solvency

Liabilities / assets8.5%
Debt / equity0.00x
Current ratio0.83x
Interest coverage-4.35x

Cash quality & payout

Operating cash flow / net income0.52x
Accruals ratio-13.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue———
R&D expense$1.63M—$98,544
SG&A expense$10.28M$1.28M$648,892
Operating income-$11.91M-$1.28M-$747,436
Interest expense$283,011$117,719$38,069
Net income-$6.00M-$1.39M-$777,694
EBITDA-$11.91M——
EPS (basic)-0.55-0.18-0.17
EPS (diluted)-0.55-0.18-0.17
Weighted avg. shares (diluted)10.88M7.90M—
Banking
Deposits$8.00M——
Balance sheet
Cash & equivalents$144,601$3,455$410,481
Short-term investments$2.00M——
Current assets$13.98M$13,057$422,076
PP&E, net$51,626——
Total assets$164.18M$13,057$422,076
Current liabilities$10.71M$1.02M$123,316
Total liabilities$10.84M$1.37M$390,207
Shareholders' equity$153.35M-$1.36M$31,869
Shares outstanding1.26M7.90M7.90M
Cash flow statement
Operating cash flow-$8.93M-$733,526-$627,790
Capital expenditure$57,333——
Free cash flow-$8.98M——
Investing cash flow-$10.06M——
Financing cash flow$20.62M$326,500$1.03M
Depreciation & amortization$5,706——
Stock-based compensation$1.57M$69,993$69,993

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.